Sign in to view content

Treatment Response to Antioxidant Supplementation Based on CFH and ARMS2Â Genetic Risk Allele Number in AREDS Patients With No AMD at Baseline

Carl C. Awh, MD, FASRS

Video
Published 2016

Related

The OASIS Trial: Efficacy and Safety Outcomes in Subjects With Full-Thickness Macular Hole
Michael Tolentino, MD
Annual Meeting Talks
2016
Vision Loss in a Patient With Primary Pulmonary Hypertension and Long-Term Use of Sildenafil
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2016
Bartonella Henselae Presenting as a Bilateral Retinochoroiditis: Clinical and Imaging Features, Diagnosis, and Natural Course
John Allen, MD
Annual Meeting Talks
2016

Category: AMD-Non-Neovascular

See more